Interesting facts
Exploring the Compound: (7S,9S)-7-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyl-tetrahydropyran-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione
This compound is a fascinating example of a complex organic molecule that exhibits a rich tapestry of functional groups and stereochemistry. A few interesting facts about this compound include:
- Complex Structure: The compound features multiple stereocenters, which means its three-dimensional structure plays a crucial role in its biological activity and reactivity.
- Natural Product Potential: The presence of amino, hydroxy, and methoxy groups suggests that this compound could be derived from or related to natural products, possibly exhibiting medicinal properties.
- Biological Significance: Compounds with similar structural motifs are often studied for their potential therapeutic effects. This particular class of molecules may interact with specific biological targets, possibly influencing pathways related to metabolism or cell signaling.
- Research Applications: Such complex molecules can serve as leads in drug discovery. They might also be useful as probes in biochemical assays or as components in materials science.
In exploring this unique compound, researchers and students alike can appreciate the beauty of organic chemistry as well as the pivotal role that intricate structures play in the development of new therapies.
As a chemistry student or enthusiast, one might reflect on the quote: "The joy of discovery is certainly the liveliest that the mind of man can ever feel." This compound epitomizes the thrill of uncovering intricate chemical relationships and their implications in science.
Synonyms
doxorubicin
Adriamycin
23214-92-8
Adriablastin
Doxorubicine
Doxorubicinum
Doxorubicina
14-Hydroxydaunomycin
14-Hydroxydaunorubicine
NDC 38242-874
CHEBI:28748
NSC 123127
(7S,9S)-7-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione
NSC-759155
80168379AG
DTXSID8021480
NSC-123127
(1S,3S)-3-glycoloyl-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranoside
5,12-Naphthacenedione, 10-((3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, (8S-cis)-
(8S,10S)-10-{[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy}-6,8,11-trihydroxy-8-(2-hydroxyacetyl)-1-methoxy-5,7,8,9,10,12-hexahydrotetracene-5,12-dione
(8S-cis)-10-((3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-5,12-naphthacenedione
hydroxydaunomycin
doxorrubicina
Adriablastine
Hydroxyldaunorubicin
(7S,9S)-7-((2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl)oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione
(8S,10S)-10-(((2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl)oxy)-6,8,11-trihydroxy-8-(2-hydroxyacetyl)-1-methoxy-5,7,8,9,10,12-hexahydrotetracene-5,12-dione
Hydroxyl Daunorubicin
RefChem:5780
DTXCID301480
L01DB01
(8S-cis)-10-((3-Amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroacetyl)-1-methoxy-5,12-naphthacenedione
245-495-6
KW-125
Doxil
Adriblastina
Doxorubicine [INN-French]
Doxorubicinum [INN-Latin]
Doxorubicina [INN-Spanish]
Hydroxydaunorubicin
Adriamycin semiquinone
Caelyx
MFCD00869292
CHEMBL53463
NCI-C01514
ADM
(7S,9S)-7-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyl-tetrahydropyran-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione
(8S,10S)-10-(((2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyltetrahydro-2H-pyran-2-yl)oxy)-6,8,11-trihydroxy-8-(2-hydroxyacetyl)-1-methoxy-7,8,9,10-tetrahydrotetracene-5,12-dione
5,12-Naphthacenedione, 10-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(2-hydroxyacetyl)-1-methoxy-, (8S,10S)-
Doxorubicin [USAN:INN:BAN]
ThermoDox
MLS000028393
C27H29NO11
Doxorubicin-hLL1
(1S,3S)-3,5,12-trihydroxy-3-(hydroxyacetyl)-10-(methyloxy)-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranoside
(1S,3S)-3,5,12-trihydroxy-3-(hydroxyacetyl)-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranoside
Adriblastina (TN)
CCRIS 739
Doxorubicin-P4/D10
HSDB 3070
EINECS 245-495-6
Doxorubicin (USAN/INN)
Doxorubicin-hLL1 conjugate
Doxorubicin-P4/D10 conjugate
Doxorubicin?
UNII-80168379AG
DOXORUBICIN [MI]
Prestwick0_000438
Prestwick1_000438
Prestwick2_000438
Prestwick3_000438
DOXORUBICIN [INN]
ADR
DOXORUBICIN [HSDB]
DOXORUBICIN [USAN]
Probes1_000151
Probes2_000129
DOXORUBICIN [VANDF]
SCHEMBL3243
DOXORUBICIN [MART.]
BSPBio_000456
BSPBio_001031
DOXORUBICIN [WHO-DD]
(1S,3S)-3-Glycoloyl-1,2,3,4,6,11-hexahydro-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1-naphthacenyl-(3-amino-2,3,6-tridesoxy-alpha-L-lyxo-hexopyranosid)
(8S,10S)-10-((3-Amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy)-8-glycoloyl-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-5,12-naphthacenedione
1,2,3,4,6,11-Hexahydro-4beta,5,12-trihydroxy-4-(hydroxyacetyl)-10-methoxy-6,11-dioxonaphthacen-1beta-yl-3-amino-2,3,6-trideoxy-alpha-L-lyxohexopyranoside
10-((3-Amino-2,3,6-trideoxy-D-lyxohexopyranosyl)oxy)-8-glycolcyl-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-5,12-naphthacenedione
Caelyx (liposomal doxorubicin)
SPBio_002395
BPBio1_000502
cid_443939
GTPL7069
orb1308571
orb2279710
Valrubicin impurity, doxorubicin
SCHEMBL29459849
BDBM22984
BDBM32022
HMS2089H06
(8S,10S)-10-((3-AMINO-2,3,6-TRIDEOXY-.ALPHA.-L-LYXO-HEXOPYRANOSYL)OXY)-8-GLYCOLOYL-7,8,9,10-TETRAHYDRO-6,8,11-TRIHYDROXY-1-METHOXY-5,12-NAPHTHACENEDIONE
5,12-NAPHTHACENEDIONE, 10-((3-AMINO-2,3,6-TRIDEOXY-.ALPHA.-L-LYXO-HEXOPYRANOSYL)OXY)-7,8,9,10-TETRAHYDRO-6,8,11-TRIHYDROXY-8-(HYDROXYACETYL)-1-METHOXY-, (8S-CIS)-
GR-319
HY-15142A
LMPK13050001
AKOS015951330
Conjugate of doxorubicin with humanized monoclonal antibody LL1 against CD74
Conjugate of doxorubicin with monoclonal antibody P4/D10 against GP120
DB00997
SMP1_000106
NCGC00024415-35
NCGC00024415-37
NCGC00024415-38
NCGC00024415-40
NCGC00024415-41
NCGC00024415-42
NCGC00024415-61
AC-37453
BP-23114
SY224845
NS00002473
14D928
C01661
D03899
EN300-120698
Epirubicin hydrochloride impurity, doxorubicin-
H11954
Q18936
BRD-K92093830-003-04-3
BRD-K92093830-003-25-8
BRD-K92093830-003-30-8
BRD-K92093830-003-31-6
BRD-K92093830-003-33-2
VALRUBICIN IMPURITY, DOXORUBICIN [USP IMPURITY]
EPIRUBICIN HYDROCHLORIDE IMPURITY C [EP IMPURITY]
DAUNORUBICIN HYDROCHLORIDE IMPURITY D [EP IMPURITY]
EPIRUBICIN HYDROCHLORIDE IMPURITY, DOXORUBICIN- [USP IMPURITY]
(7S,9R)-7-[(2S,4S,5S,6S)-4-Amino-5-hydroxy-6-methyl-oxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione
(7S,9S)-7-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyl-tetrahydropyran-2-yl]oxy-9-glycoloyl-6,9,11-trihydroxy-4-methoxy-8,10-dihydro-7H-tetracene-5,12-quinone;hydrochloride
(7S,9S)-7-[(2R,4S,5S,6S)-4-azanyl-6-methyl-5-oxidanyl-oxan-2-yl]oxy-4-methoxy-6,9,11-tris(oxidanyl)-9-(2-oxidanylethanoyl)-8,10-dihydro-7H-tetracene-5,12-dione;hydrochloride
(7S,9S)-7-[(4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione
(7S,9S)-7-[[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyl-2-oxanyl]oxy]-6,9,11-trihydroxy-9-(2-hydroxy-1-oxoethyl)-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione;hydrochloride
(8S,10S)-10-[[(2R,4S,5S,6S)-4-Amino-5-hydroxy-6-methyl-2-tetrahydropyranyl]oxy]-6,8,11-trihydroxy-8-(2-hydroxyacetyl)-1-methoxy-7,8,9,10-tetrahydrotetracene-5,12-dione
(8S-cis)-10-[(3-Amino-2,3,6-trideoxy-.alpha.-L-lyxo-hexopyranosyl]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-5,12-naphthacenedione
1392315-46-6
5,12-Naphthacenedione, 10-((3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, (8S,10S)-
5,12-Naphthacenedione, 10-[(3-amino-2,3,6-trideoxy-|A-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(2-hydroxyacetyl)-1-methoxy-, (8S,10S)-
Solubility of (7S,9S)-7-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyl-tetrahydropyran-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione
The solubility of complex compounds like (7S,9S)-7-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyl-tetrahydropyran-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione can vary significantly due to their intricate structures. Here are some factors to consider when assessing the solubility of this compound:
Overall, while the intricate structure of this compound presents challenges for solubility predictions, careful consideration of these key factors can provide insights into its behavior in various solvent systems. As a generalization, one might say that the solubility profile of complex organic compounds tends to be unique, warranting experimental validation to fully understand their solubility characteristics.